Mark Zuckerberg backs $500 million push to build AI models of human cells as part of long-term effort to cure disease.
OpenAI has released GPT-Rosalind, a large language model fine-tuned specifically for life sciences research, marking the company’s most direct push yet into computational biology and drug discovery.